<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552370</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4045</org_study_id>
    <nct_id>NCT00552370</nct_id>
  </id_info>
  <brief_title>Glycemic Optimization Treatment Study</brief_title>
  <acronym>GOT</acronym>
  <official_title>A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus®(Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®,&#xD;
      each of varying intensity and defined by their end-of -study target for self monitored plasma&#xD;
      glucose(SMPG), in patients with Type 2 diabetes mellitus, with inadequate glycemic control&#xD;
      (A1C greater than or equal to 7.0%) on oral antidiabetic drug therapy(OAD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®, each of varying intensity and defined by their end-of-study target for self monitored blood glucose (SMBG).</measure>
    <time_frame>From the start to the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the number of subjects whose final A1c is &lt;7.0% at the end of the study for the 5 dosing algorithms.</measure>
    <time_frame>From the start to the end of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">5062</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must give their signed informed consent.&#xD;
&#xD;
          2. Diagnosis of Type 2 DM for at least 6 months.&#xD;
&#xD;
          3. Males and females greater than or equal to 18 years of age.&#xD;
&#xD;
          4. A1c greater than or equal to 7.0%.&#xD;
&#xD;
          5. Current (last 2 months) diabetes therapy with oral anti-hyperglycemia agents only.&#xD;
&#xD;
          6. Demonstrated willingness and ability to inject insulin glargine.&#xD;
&#xD;
          7. Able to understand and willing to comply with procedures required by the protocol and&#xD;
             have access to a phone.&#xD;
&#xD;
          8. Demonstrated ability and willingness to perform self-monitoring of blood glucose&#xD;
             (SMBG) and use of the algorithm calculator (AL-CAL).&#xD;
&#xD;
          9. BMI greater than 25.0 kg/m2.&#xD;
&#xD;
         10. Subjects who, in the opinion of the investigator, should be initiated on insulin&#xD;
             therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac status New York Heart Association (NYHA) III-IV (Appendix A).&#xD;
&#xD;
          2. For subjects treated with metformin (Glucophager, Glucophage XRr, Glucovancer,&#xD;
             Metaglipr , or Avandametr) plus a serum creatinine greater than 1.5 mg/dL (133 μmol/L)&#xD;
             for males or greater than 1.4 mg/dL (124 μmoL) for females, the inability or&#xD;
             unwillingness to discontinue these medications, and to remain off them through the&#xD;
             entire study.&#xD;
&#xD;
          3. For subjects on thiazolidinediones, the inability or unwillingness to discontinue&#xD;
             these medications and to remain off them through the entire study.&#xD;
&#xD;
          4. Planned pregnancy, pregnancy, or lactation.&#xD;
&#xD;
          5. Serum creatinine greater than 3.0 mg/dL (266 μmol/L).&#xD;
&#xD;
          6. Serum glutamic pyruvic transaminase (SGPT) greater than 2.5 x the upper limit of&#xD;
             normal range.&#xD;
&#xD;
          7. Any current malignancy or cancer within the past 5 years (except adequately treated&#xD;
             basal cell carcinoma or cervical carcinoma in situ).&#xD;
&#xD;
          8. Diagnosis of dementia or mental condition rendering the subject unable to understand&#xD;
             the nature, scope, and possible consequences of the study.&#xD;
&#xD;
          9. Hypersensitivity to Lantus® insulin or any of its components.&#xD;
&#xD;
         10. Any disease or condition, including the abuse of illicit drugs, prescription&#xD;
             medicines, or alcohol that, in opinion of the sponsor/investigator, may interfere with&#xD;
             the completion of the study.&#xD;
&#xD;
         11. Current (last 2 months) insulin therapy.&#xD;
&#xD;
         12. With the exception of thiazolidinediones (for all potential subjects) and for subjects&#xD;
             who are taking metformin and have an exclusionary creatinine level, the ability or&#xD;
             unwillingness to continue pre-study anti-hyperglycemia agents at pre-study dosages&#xD;
             through the entire study.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Barch</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2007</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

